txGABAergic neurons cell therapy - bit.bio therapeutics
Latest Information Update: 22 Dec 2023
At a glance
- Originator bit.bio
- Class Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Epilepsy
Most Recent Events
- 04 Dec 2023 txGABAergic neurons cell therapy - bit.bio therapeutics is available for licensing as of 04 Dec 2023 (bit.bio therapeutics website, December 2023)
- 04 Dec 2023 Early research in Epilepsy in United Kingdom (Parenteral) (bit.bio therapeutics pipeline, December 2023)
- 11 Jul 2023 bit.bio has patent protection for opti-ox technology in USA